Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.58 |
| ▸ | HMGCR | P04035 | 9/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247234 | 0.84 | HMGCR (0.74) | RXRAHMGCR | |
| SCHEMBL7481306 | 0.84 | HMGCR (0.74) | RXRAHMGCR | |
| SCHEMBL247233 | 0.84 | HMGCR (0.74) | RXRAHMGCR | |
| SCHEMBL10049194 | 0.84 | HMGCR (0.60) | RXRAHMGCRNR1I2NR4A2PDE4D | |
| SCHEMBL9301248 | 0.84 | HMGCR (0.74) | RXRAHMGCR | |
| SCHEMBL7481310 | 0.84 | HMGCR (0.74) | RXRAHMGCR | |
| SCHEMBL13349654 | 0.82 | HMGCR (0.57) | RXRAHMGCRNR1I2NR4A2PDE4D | |
| SCHEMBL13316786 | 0.80 | HMGCR (0.55) | RXRAHMGCRNR1I2NR4A2PDE4D | |
| SCHEMBL13980281 | 0.80 | HMGCR (0.57) | RXRAHMGCRNR1I2NR4A2PDE4D | |
| SCHEMBL10153055 | 0.79 | RXRA (0.62) | RXRAHMGCRNR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010077062-A2 | PREPARATION METHOD OF STATIN COMPOUND AND BENZOTHIAZOLYL SULFONE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | RXRA 695/4885HMGCR 2/4885NR1I2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.